Loading...
XSHG600422
Market cap1.71bUSD
Dec 24, Last price  
16.50CNY
1D
-2.14%
1Q
27.91%
Jan 2017
22.13%
Name

KPC Pharmaceuticals Inc

Chart & Performance

D1W1MN
XSHG:600422 chart
P/E
28.09
P/S
1.62
EPS
0.59
Div Yield, %
1.17%
Shrs. gr., 5y
-0.39%
Rev. gr., 5y
1.64%
Revenues
7.70b
-6.99%
673,674,6661,207,634,6501,146,552,9311,290,258,2401,310,931,3401,434,908,6641,817,237,6392,434,008,1023,016,021,8003,584,294,9194,120,509,1504,915,685,8735,100,597,1225,852,287,4327,101,977,6758,119,963,3207,717,086,9358,253,532,5048,282,063,4567,703,121,256
Net income
445m
+16.05%
91,778,691017,830,29129,068,89132,118,03658,323,07985,577,950130,122,930181,750,108231,623,314292,237,273420,850,831407,256,142330,096,566335,535,842454,309,421456,856,228507,667,600383,183,590444,679,961
CFO
356m
+40.25%
0061,248,863130,059,18091,588,904128,569,83990,820,592140,236,287213,330,130241,969,668379,126,295476,617,134311,157,102242,534,997352,074,123429,500,909409,939,216251,628,491253,895,474356,083,160
Dividend
Jul 31, 20240.2 CNY/sh

Profile

KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.
URL
http://www.kpc.com.cn/
IPO date
Dec 06, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,703,121
-6.99%
8,282,063
0.35%
8,253,533
6.95%
Cost of revenue
6,513,974
7,428,498
7,437,008
Unusual Expense (Income)
NOPBT
1,189,147
853,565
816,525
NOPBT Margin
15.44%
10.31%
9.89%
Operating Taxes
109,477
91,827
118,075
Tax Rate
9.21%
10.76%
14.46%
NOPAT
1,079,670
761,738
698,450
Net income
444,680
16.05%
383,184
-24.52%
507,668
11.12%
Dividends
(146,597)
(204,729)
(174,171)
Dividend yield
0.93%
1.93%
2.08%
Proceeds from repurchase of equity
(2,159)
BB yield
0.01%
Debt
Debt current
726,487
1,034,835
678,022
Long-term debt
196,038
149,538
200,449
Deferred revenue
207,577
245,338
Other long-term liabilities
100,893
77,580
56,667
Net debt
(1,516,462)
(794,633)
(974,018)
Cash flow
Cash from operating activities
356,083
253,895
251,628
CAPEX
(65,482)
Cash from investing activities
(328,783)
19,375
Cash from financing activities
(201,841)
67,799
FCF
910,408
534,604
285,063
Balance
Cash
2,096,806
1,977,793
1,734,754
Long term investments
342,182
1,213
117,735
Excess cash
2,053,831
1,564,903
1,439,812
Stockholders' equity
3,954,436
4,019,907
3,808,889
Invested Capital
4,585,477
4,832,969
4,443,067
ROIC
22.93%
16.42%
16.47%
ROCE
17.89%
13.32%
13.84%
EV
Common stock shares outstanding
753,695
751,340
758,256
Price
20.86
47.73%
14.12
27.78%
11.05
27.75%
Market cap
15,722,075
48.20%
10,608,926
26.62%
8,378,726
27.60%
EV
14,384,738
9,973,792
7,561,687
EBITDA
1,392,755
1,062,366
1,000,326
EV/EBITDA
10.33
9.39
7.56
Interest
19,310
40,731
33,586
Interest/NOPBT
1.62%
4.77%
4.11%